drugset / Trial / NCT00351039
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
Phase 1/2
Terminated
8 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II trial of elderly patients (\> 70 years of age). Patients in this age group with previously un-treated Advanced Stage Non-Squamous Non-Small Cell Lung Cancer (NSCLC) with Stage IIIB (with malignant pleural effusion) and stage IV disease will be enrolled. Therapy consists of three drugs (Premetrexed\[Alimta™\], Bevacizumab and Erlotinib\[Tarceva™\]) which are given every 28 days.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |